Latest News - Amgen
Top Corporates Hub
Amgen
Novo Nordisk's Wegovy Pill Escalates Eli Lilly Rivalry
09.07.2026 08:46
Novo Nordisk regains competitive ground in obesity with the strong launch of the Wegovy pill, reversing some of the recent underperformance against Eli Lilly.
Amgen (AMGN) Recalls Put Its Valuation Story Back In Focus
08.07.2026 03:15
Amgen (AMGN) has moved into focus after initiating voluntary nationwide recalls of certain Corlanor and Sensipar tablet lots due to foreign substances and CGMP deviations, prompting investors to reassess drug quality and compliance risks. See our latest analysis for Amgen. Against this recall backdrop, Amgen’s recent momentum has stayed intact, with a 30 day share price return of 5.30% and a year to date share price return of 12.35%. The 1 year total shareholder return of 27.66% and 3 year...
The Cancer Therapy Strategy VERAXA Is Betting the Company On
06.07.2026 16:00
By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it expects BiTAC molecules to be the company’s main value drivers and to dominate its pipeline development in the upcoming years, hence receiving VERAXA’s main share of investments to have a first BiTAC-T cell engager candidate ready by early 2028. The company stated its half-year progress […] The post The Cancer Therapy Strategy VERAXA Is Betting the Company On appeared first on ExecEdge.
Amgen (AMGN) Upgraded to Buy: What Does It Mean for the Stock?
06.07.2026 16:00
Amgen (AMGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Allarity Therapeutics, Inc. (ALLR) Stock Outpacing Its Medical Peers This Year?
06.07.2026 13:40
Here is how Allarity Therapeutics, Inc. (ALLR) and Amgen (AMGN) have performed compared to their sector so far this year.
Amgen (AMGN) Stock Is Up, What You Need To Know
03.07.2026 00:28
Shares of biotech company Amgen (NASDAQ:AMGN) jumped 3.1% in the afternoon session after the company received a favorable court ruling that blocked a first-of-its-kind state price cap on its blockbuster drug, Enbrel.
Roche KRAS drug succeeds in head-to-head lung cancer study
02.07.2026 10:19
The Phase 3 trial compared Roche’s divarasib with treatments sold by Amgen and Bristol Myers in patients with non-small cell lung cancer.
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
02.07.2026 05:50
Experimental drug, divarasib, showed meaningful improvements in both patients’ overall survival and the time they survived without the disease worsening.
Medical journal retracts Tavneos pivotal paper amid wider regulatory clampdown
01.07.2026 11:06
This further weakens Amgen’s case for Tavneos’ continued use on the market as the drug comes under intense regulatory scrutiny.
Mizuho Highlights Amgen (AMGN) Pipeline Potential With MariTide and Olpasiran
01.07.2026 10:15
Amgen Inc. (NASDAQ:AMGN) ranks among the top NASDAQ stocks for retirement. On June 16, Mizuho increased its price target for Amgen Inc. (NASDAQ:AMGN) to $303 from $295 while keeping a Neutral rating on the company’s shares, with the firm highlighting MariTide and olpasiran as crucial focal points for the company. Mizuho said that Novartis and […]
Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech
30.06.2026 09:03
Vertex Pharmaceuticals Incorporated offers predictable CF cash flows and pipeline catalysts in pain, hematology & renal (Pove for IgAN). Click for this VRTX update.
Amgen (AMGN) Stock Weighs Strong Run Against Mixed Valuation Signals
30.06.2026 08:15
If you are wondering whether Amgen stock still offers value at current levels, this article walks through what the numbers are actually saying about the price you see on screen. Amgen shares last closed at US$360.55, with returns of 3.9% over the past week, 7.1% over the past month, 10.0% year to date, 27.8% over one year, 75.7% over three years, and 73.2% over five years. This gives investors plenty of price history to weigh against today’s valuation. Recent attention on Amgen has been...
Amgen's Tavneos Faces EU Revocation After CHMP Review
26.06.2026 12:21
The European Medicines Agency said Friday that its Committee for Medicinal Products for Human Use (C
Piper Sandler and Morgan Stanley Highlight Amgen (AMGN) on Pipeline Strength and Obesity Drug Potential
26.06.2026 11:11
Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy right now. On June 12, Piper Sandler reaffirmed its Overweight rating and $427 price target for Amgen Inc. (NASDAQ:AMGN). The firm published a detailed review of the Sjogren’s syndrome therapeutic development environment in advance of Amgen’s CD40 ligand-directed fusion protein dazodalibep’s Phase III conclusion […]
2 Healthcare Stocks to Consider Right Now and 1 We Brush Off
25.06.2026 09:13
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately - over the past six months, healthcare stocks have gained 7.6%, nearly mirroring the S&P 500.
Viatris Soared 54%: Time To Be More Careful (Rating Downgrade)
23.06.2026 12:55
Viatris Inc. hits a 52-week high, driven by a strong late-stage pipeline, but shares corrected on Effexor sales decline. Click for this VTRS update.
Willful Patent Infringement Verdict Might Change The Case For Investing In Amgen (AMGN)
23.06.2026 00:13
In June 2026, a Delaware jury ruled that Amgen and its subsidiary Teneobio willfully infringed Harbour BioMed’s Grosveld patent, awarding Harbour US$20,203,704 in damages with the option to seek a tripling of that amount. The verdict, in one of the most closely watched antibody technology patent disputes, highlights legal and financial exposure around Amgen’s antibody discovery platforms and broader IP posture. We’ll now examine how this willful infringement verdict and potential higher...
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026?
19.06.2026 17:10
Amgen posts strong profits and cash flow, while NovoCure pursues growth with a direct-to-patient cancer therapy model and leaner balance sheet.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
19.06.2026 13:00
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape
15.06.2026 00:01
Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that a jury in the United States District Court for the District of Delaware has returned a decisive verdict in the Company's favor in the patent infringement lawsuit against Amgen Inc., and Teneobio, Inc. (an Amgen subsidiary) (together, "Amgen").The verdict represents a complete victory f